Marcus Schindler
Chief Tech/Sci/R&D Officer bei NOVO NORDISK A/S
Profil
Marcus Schindler ist Chief Scientific Officer & Executive VP-Research bei Novo Nordisk A. Er promovierte an der Universität von Cambridge.
Aktive Positionen von Marcus Schindler
| Unternehmen | Position | Beginn |
|---|---|---|
| NOVO NORDISK A/S | Chief Tech/Sci/R&D Officer | 01.03.2021 |
Ehemalige bekannte Positionen von Marcus Schindler
| Unternehmen | Position | Ende |
|---|---|---|
| INNATE PHARMA | Director/Board Member | 28.05.2021 |
| The Oxford | Chief Tech/Sci/R&D Officer | 29.02.2008 |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Chief Tech/Sci/R&D Officer | - |
AstraZeneca A/S /Denmark/
 AstraZeneca A/S /Denmark/ Pharmaceuticals: MajorHealth Technology AstraZeneca A/S sells and distributes pharmaceutical products to the health sector. It specializes within therapy areas of the gastrointestinal diseases, respiratory diseases, cardiovascular diseases, neuroscience, and oncology. The company was founded in 1943 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Ausbildung von Marcus Schindler
| University of Cambridge | Doctorate Degree |
| University of Gottingen | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| INNATE PHARMA | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| The Oxford | Consumer Services |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
AstraZeneca A/S /Denmark/
AstraZeneca A/S /Denmark/ Pharmaceuticals: MajorHealth Technology AstraZeneca A/S sells and distributes pharmaceutical products to the health sector. It specializes within therapy areas of the gastrointestinal diseases, respiratory diseases, cardiovascular diseases, neuroscience, and oncology. The company was founded in 1943 and is headquartered in Copenhagen, Denmark. | Health Technology |
